Skip to main content
. 2011 May 31;16(6):730–741. doi: 10.1634/theoncologist.2010-0318

Figure 4.

Figure 4.

Progression-free survival (PFS) and overall survival (OS) with everolimus (A) and perifosine (B) in patients with relapsed or refractory Waldenström's macroglobulinemia.

(A) Reprinted from Ghobrial IM, Gertz M, LaPlant B et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. J Clin Oncol 2010;28:1408–1414. Reprinted with permission. © 2010 American Society of Clinical Oncology. All rights reserved.

(B) Adapted and reprinted by permission from the American Association for Cancer Research: Ghobrial IM, Roccaro A, Hong F et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clin Cancer Res 2010;16:1033–1041.